Based on a simple E.coli growth inhibition assay, the authors trained a model capable of identifying antibiotic potential in compounds structurally divergent from conventional antibiotic drugs. One of the predicted active molecules, Halicin (SU3327), was experimentally validated in vitro and in vivo. Halicin is a drug under development as a treatment for diabetes. This model contains a reduced version of the model for training purposes. Please use the eos4e40 for the full prediction capabilities.
- EOS model ID:
eos4e41 - Slug:
chemprop-antibiotic-lite
- Input:
Compound - Input Shape:
Single - Task:
Classification - Output:
Probability - Output Type:
Float - Output Shape:
Single - Interpretation: Probability that a compound inhibits E.coli growth. The inhibition threshold was set at 80% growth inhibition in the training set.
- Publication
- Source Code
- Ersilia contributor: GemmaTuron
If you use this model, please cite the original authors of the model and the Ersilia Model Hub.
This package is licensed under a GPL-3.0 license. The model contained within this package is licensed under a MIT license.
Notice: Ersilia grants access to these models 'as is' provided by the original authors, please refer to the original code repository and/or publication if you use the model in your research.
The Ersilia Open Source Initiative is a Non Profit Organization (1192266) with the mission is to equip labs, universities and clinics in LMIC with AI/ML tools for infectious disease research.
Help us achieve our mission!